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Published research shows small-to-medium effects of 
Cognitive Behavioral Therapy for Psychosis (CBTp) 
on reducing psychotic symptoms. Given the on-going 
development of  CBTp interventions, the aim of this 
systematic review is to examine whether the effective-
ness of  CBTp has changed across time. MEDLINE, 
EMBASE, PsycINFO, and CENTRAL were searched 
for randomized controlled trials examining CBTp 
interventions targeting positive and/or negative 
symptoms vs treatment as usual. Four meta-analyses 
were carried out to examine the effectiveness of  CBTp 
for: positive symptoms; delusions; hallucinations; and 
negative symptoms. Four meta-regressions examined 
whether the effectiveness of  CBTp changed across time 
for these groups of  symptoms. A  total of  28 studies 
(n  =  2698) yielded a pooled g of  −0.24 (95% confi-
dence interval [CI] −0.32, −0.16, P < .001) favoring 
CBTp for positive symptoms, with nonsignificant het-
erogeneity (Q  =  26.87, P  =  .47; I2 =0%); 13 studies 
(n = 890) yielded a pooled g of  −0.36 (95% CI −0.59, 
−0.13, P =  .002) for delusions, with substantial heter-
ogeneity (Q  =  31.99, P  =  .001; I2 =62%); 16 studies 
(n = 849) yielded a pooled g of  −0.26 (95% CI −0.42, 
−0.11, P < .001) for hallucinations, with nonsignificant 
heterogeneity (Q  =  18.10, P  =  .26; I2 =17%); 19 
studies (n = 1761) yielded a pooled g of  −0.22 (95% CI 
−0.33, −0.12, P < .001) for negative symptoms, with 
nonsignificant heterogeneity (Q  =  20.32, P  =  .32, I2 
=11%). Meta-regressions indicated a significant effect 
of  year on the effectiveness of  CBTp only for delusions 
(F[1,  11]  =  5.99, P  =  .032; R2  =  0.594); methodolog-
ical quality did not effect this finding. Findings indi-
cate small-to-medium effects of  CBTp for psychotic 
symptoms, with increasing effectiveness across time for 
delusions.
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Introduction
Over their lifetime, approximately 1% of the UK pop-
ulation will receive a diagnosis of schizophrenia.1 The 
complexity of this condition puts pressure on services 
to provide effective treatments. The National Institute 
for Care and Health Excellence (NICE) recommends 
Cognitive Behavior Therapy for Psychosis (CBTp) as 
one of the psychological treatments for psychosis.2 
A  recent meta-analysis reported that CBTp had small 
effects on psychotic symptoms, and the authors subse-
quently questioned whether CBTp should continue to 
be a recommended treatment.3 McKenna and Kingdon 
have similarly argued that CBTp has been “oversold” as a 
treatment for psychosis.4
Meta-analyses have consistently reported small-to-
moderate effects of CBTp on psychotic symptoms. One 
meta-analysis reported an effect of 0.25 for positive 
symptoms when CBTp was compared with a control 
intervention and an effect size of 0.31 when CBTp was 
compared with treatment as usual (TAU).3 When aspects 
of bias were considered, the effect sizes decreased. 
Another meta-analysis reported an effect size of 0.37 
for positive symptoms, although, when methodological 
quality was taken into account, the effect size for the high-
quality studies reduced and was 0.22 against 0.49 for the 
low-quality studies.5 A more recent meta-analysis found a 
small effect of 0.16 for positive symptoms favoring CBTp 
vs other psychological interventions.6
Bentall proposed that examining individual psychotic 
symptoms, such as delusions and hallucinations, could 
be particularly helpful as it could lead to identifying 
symptom-specific psychological mechanisms that could 
be targeted in therapy.7 Steele et al similarly suggest that 
exploring the positive syndrome could lead to missing out 
on the multidimensional nature of individual symptoms.8 
When types of positive symptoms were assessed sep-
arately, one meta-analysis found an effect size of 0.44 
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favoring CBTp for hallucinations and an effect size of 
0.36 favoring CBTp for delusions when compared with 
the control group (TAU or an active control or a combi-
nation of both).9 Another meta-analysis found an effect 
size of 0.27 favoring CBTp for delusions when compared 
with TAU.10
In terms of negative symptoms, one meta-analysis re-
ported an effect size of 0.44 favoring CBTp, although, 
when the studies were divided by methodological quality, 
the effect size for the high-quality studies reduced and 
was 0.21 against 0.61 for the low-quality studies,5 once 
again pointing to the importance of considering method-
ological quality. Another meta-analysis reported partic-
ularly low effect sizes for CBTp on negative symptoms: 
0.08 when compared with a control intervention and 0.13 
when compared with TAU.3 As with positive symptoms, 
when aspects of bias were taken into consideration, the 
effect sizes decreased further. This low effect size may also 
reflect the focus of the clinical interventions. One meta-
analysis, eg, found that most studies assessed negative 
symptoms as secondary treatment targets rather than pri-
mary targets.11 The authors argued that the clinical focus 
on positive symptoms, and the measurement of these as 
primary outcomes limits our understanding of the actual 
effect of CBTp targeting negative symptoms. Others have 
made similar claims, suggesting that cognitive-behavioral 
therapists have devoted more time to understanding and 
addressing positive symptoms. This focus could lead to 
a poorer understanding of negative symptoms and ex-
plain why they are usually the secondary outcomes in 
randomized controlled trials (RCTs).12
As described above, meta-analytic reviews have shown 
differing effect sizes for the symptom-based outcomes, 
and difference in the methodological quality of trials has 
been shown to be important. Another likely reason for 
the variation is the difference in clinical focus between 
trials—some interventions target differing symptoms of 
psychosis, such as delusions or hallucinations. Another 
explanation for differences in effect sizes could be that 
clinical practice has evolved and that the delivery of 
CBTp has improved over time. Since the early trials of 
CBTp, the intervention has moved from challenging and 
disputing the content of delusions and/or hallucinations 
to focusing on changing service users’ relationship with 
their symptoms. This evolution reflects a theoretical 
shift: it is not the content of thoughts that need to be 
addressed but rather the interpretation of the thoughts 
(ie, meta-cognition).13 In addition to the evolution of 
CBTp, there have been advances in the understanding 
of the psychological mechanisms that could contribute 
to the formation, maintenance, and experience of psy-
chotic symptoms: such as the role of emotion,14 arousal,15 
self-esteem,16 attachment,17 interpersonal issues,18 and 
loss and trauma.19 Understanding these psychological 
mechanisms may permit more targeted treatment within 
the CBTp framework for service users, with their variety 
of personal histories, views of the world, and psychotic 
difficulties.20
A recent meta-analysis examined whether the effective-
ness of CBT for symptoms of depression changed across 
time.21 The authors found a decrease in effectiveness over 
time, where studies with earlier publication dates had 
larger effect sizes than more recent publications. The 
authors suggested that the declining treatment outcomes 
could be a reflection of the quality of the intervention, 
specifically the degree of clinician experience and the fi-
delity to the manual.
In psychosis research, there is a need to explore the 
effectiveness of CBTp across time, at least for posi-
tive symptoms. In a recent meta-analysis of negative 
symptoms, a meta-regression of the effects of CBTp was 
implemented by dividing the year of publication into four 
chronological clusters.11 The findings showed a decreasing 
effect, with better treatment outcomes for studies with an 
earlier publication date. The researchers also explored the 
impact of treatment focus and found that studies with 
strong behavioral interventions had larger effect sizes 
(Hedges’ g = 0.25) compared with studies that had fewer 
behavioral components (Hedges’ g = 0.02). They demon-
strate a change in treatment over time; a shift away from 
the behavioral components reduced effect sizes, although 
they also found that higher quality trials were associated 
with lower effect sizes. This points to a need to consider 
trial quality as a factor when exploring change over time.
We carried out a systematic review of the effective-
ness of CBTp across time, with separate analyses for 
positive symptoms, delusions, hallucinations, and nega-
tive symptoms; we also explored methodological quality. 
Our first hypothesis was that we would find an increase 
in the effectiveness of CBTp across time for positive 
symptoms and for hallucinations and delusions when 
these symptoms were assessed individually. Our second 
hypothesis was that there would not be an increase in the 
effectiveness of CBTp across time for negative symptoms.
Methods
Electronic searches of MEDLINE, EMBASE, 
PsycINFO, and CENTRAL were conducted on April 26, 
2018 without a date restriction. Bibliographic references 
from previous meta-analytic reviews3,9 were manually 
searched for studies that may not have been identified by 
the search strategy, which is available in supplementary 
material S1.
Criteria for Study Inclusion/Exclusion
Studies included were parallel-group RCTs, single-blind 
RCTs, and open RCTs. Participants were those who expe-
rienced positive and/or negative symptoms from all mental 
health settings, including At-Risk-Mental-State (ARMS) 
participants. ARMS participants are at a preclinical 
stage and are considered at a higher risk of developing 
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psychosis than the general population. The inclusion cri-
terion for the intervention group was individual or group 
CBTp or cognitive therapy (CT) that targeted positive or 
negative symptoms. The NICE guidelines2 and a descrip-
tion of the components of CBTp from a Delphi study22 
were used in evaluating whether studies were delivering 
CBTp. If  a study used other therapeutic elements, eg, 
family interventions, it was included if  the CBTp was the 
predominant intervention. The inclusion criterion for the 
control group was TAU, which was conceptualized as the 
accepted usual treatment that was part of routine prac-
tice within the service where the RCT was delivered. Only 
outcomes that were researcher-rated at the end of treat-
ment for positive or negative symptoms were included. 
Unless stated, it was assumed that the outcome measures 
were researcher-rated rather than client self-reported.
Unpublished studies and studies not in the English 
language were excluded. Studies including only children 
(under age 18) were excluded. Studies where participants 
had comorbid difficulties, such as recent history of vi-
olent behavior, cognitive impairment, or substance use, 
were also excluded. Studies were excluded if  the interven-
tion was integrative rather than predominantly CBTp. 
Studies were excluded if  CBTp was compared with an-
other intervention that was not considered TAU. Studies 
that described only self-reported outcomes were also 
excluded. A summary of the inclusion/exclusion criteria 
is available in supplementary material S2.
Methodological Quality and Bias
Since methodological quality of RCTs has been proposed 
as a possible source of funnel plot asymmetry,23 where 
lower quality trials may show larger intervention 
effects compared with higher quality trials,24 the RCT-
Psychotherapy Quality Rating Scale (RCT-PQRS) and 
the Cochrane Risk of Bias Tool were used to evaluate 
studies included in the meta-analysis.
The RCT-PQRS25 is a 25-item scale that assesses the 
quality of psychotherapies in RCTs. Items 1–24 are rated 
on a 0–2 Likert scale. A  score of “0” reflects a poorly 
described and executed study design element; a score of 
“1” reflects a moderately described and executed study 
design element or a well described but poorly executed 
study design element or a poorly described but well ex-
ecuted study design element; and a score of “2” reflects 
a well justified, described, and executed study design ele-
ment. Item 25, which is the omnibus quality rating of the 
whole study, is rated on a Likert scale from 1 to 7, where 
“1” reflects exceptionally poor quality and “7” reflects ex-
ceptionally good quality. All 25 items are grouped into six 
domains: description of subjects, definition and delivery 
of treatment, outcome measures, data analysis, treatment 
assignment, and overall quality of the study. To deter-
mine the omnibus quality rating (a score of 1–7) for each 
study, all subscales were averaged, then an overall average 
of the subscales was scaled on a 7-point rating scale; 
Cronbach’s α = .87.
The Cochrane Risk of Bias Tool26 has five domains: 
selection bias, performance bias, attrition bias, reporting 
bias, and other bias. There are two parts to assessment 
within each domain item. First, the magnitude of risk of 
bias is judged as low, high, or unclear—using the guidance 
provided in the assessment tool. Second, text descriptions 
of the trial characteristics on which the judgments of risk 
of bias are based can be included to ensure transparency 
and to show support for the decision.
Stages of the Review and Meta-analysis
Author K.S. devised the search strategy with input from 
an information specialist. K.S.  screened eligible studies 
twice to ensure that no studies were missed. Interrater 
reliability from a random selection of studies at the 
screening stage was calculated using ratings from another 
reviewer—S.R., a research assistant. Any disagreements 
between K.S. and S.R. were first discussed between them-
selves; if  consensus was not reached authors, B.B.  and 
C.M. were included in the discussion and a consensus de-
cision was made. Data extraction including methodolog-
ical quality and bias was carried out by K.S.. Interrater 
reliability for methodological quality and bias was cal-
culated using S.R.’s ratings from a random selection of 
studies.
Data Analytic Plan
Effect sizes were computed using Review Manager27 
(RevMan; version 5.3) using the random-effects model. 
The random-effects model assigns study weights, allowing 
studies that yield a more precise estimate to carry more 
importance.28 To examine whether the effectiveness of 
CBTp has improved over time for positive symptoms, 
delusions, hallucinations, and negative symptoms, four 
meta-regression analyses were carried out using the 
Statistical Package for the Social Sciences (SPSS; version 
24) software.29 The linear regression analysis was selected 
using the year of publication as the independent variable 
and Hedges’ g effect sizes from RevMan as the dependent 
variable. Higgins and Thompson proposed that a meta-
regression should be weighted to take into account both 
within-study and between-studies variance.30 All meta-
regressions used weights produced in RevMan, which 
were inserted into the “WLS weight” option in the linear 
regression.
Since Pickering et  al proposed that co-occurring 
symptoms may confound predictors,31 hallucinations 
were adjusted for when examining delusions and vice 
versa in the additional analyses. As it can be argued that 
the methodological quality of RCTs assessing CBTp may 
have changed across time, additional analyses including 
methodological quality were implemented where we 
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found significant effect of year of publication on effect 
size. The methodological quality scores from the RCT-
PQRS were entered into the linear regression to assess 
whether it confounded the relationship between the year 
of publication and the observed effect sizes and also to 
assess for moderation using the interaction term RCT-
PQRS × YEAR.
Publication bias was examined using the Begg and 
Mazumdar’s Rank Order Correlation test,32 Egger’s 
regression intercept test,33 and Duval and Tweedie’s 
trim-and-fill procedure34 using the Comprehensive Meta-
Analysis software (version 3).35
Additional Analyses Undertaken
Additional analyses were computed when examining the 
effects of CBTp for positive symptoms. The inclusion 
criteria included RCTs where participants experienced 
positive or negative symptoms. Trials that examined 
ARMS were, therefore, included.36,37 Since this popula-
tion differs from those who have experienced first episode 
psychosis or recurrent psychosis, a separate meta-analysis 
was carried out excluding the two ARMS studies to ex-
amine whether this affected the observed pooled effect 
size. Two studies were self-guided and one was based on 
virtual reality (VR); another separate analysis was carried 
out excluding these three studies.38–40 Finally, in terms of 
negative symptoms, one study used a scale that was not 
accessible, and we could, therefore, not be sure that it was 
measuring negative symptoms.41 Although we excluded 
this study from the main analysis, we conducted a sepa-
rate meta-analysis with it included to examine its impact 
on the pooled estimate.
Results
The systematic literature search produced 3451 titles. 
After the initial duplicate copies were removed, 2407 
remained and were screened by title and abstract; 218 of 
these articles were included in the final screening phase 
yielding 29 studies that were eligible for analysis as shown 
in figure  1. These studies were published between 1998 
and 2018.
Additional Study Exclusions and Considerations
One study was excluded because the outcomes were self-
reported at baseline and researcher-rated at the end of 
treatment.42 We considered that this lack of consistency 
could have affected outcomes. Another study reported 
only state paranoia scores—how the individual felt 
within the past 15 min.43 We excluded this study because 
this method of measurement significantly deviated from 
the other included studies. In one study, two participants 
in the CT group and one in the TAU group self-reported 
at the end of treatment44; this was included as the rest of 
the outcome data were researcher-rated. One study45 was 
excluded because it did not report the end-of-treatment 
data, and we were unable to access those data from the 
authors. Several studies that focused on prioritizing other 
service user difficulties, such as anxiety or depression,46 
were excluded as not all participants received the same in-
tervention. RCTs that delivered CBTp but only to service 
users who exhibited warning signs of potential relapse 
were also excluded as not all service users received the 
same intervention.47
Several of the studies retrieved were based on the same 
data set. In cases where data could not be extracted from 
the original article because, eg, they were missing, incom-
plete, or presented in change scores, the article with the 
most complete statistical information was sought, al-
though the original article was cited.48,49 Characteristics 
of the included studies are shown in table 1.
Interrater Reliability
From the initial 2407 titles, 406 (17%) were randomly 
selected for reliability testing. The agreement rate was 
Figure 1. PRISMA diagram of the studies included in the 
meta-analysis.
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98%. We agreed to “exclude” 390 studies, “include” 5 
studies, and “could not tell” for 2 of the studies. The dis-
agreement rate was 2% with 2 ratings being “include” 
vs “exclude,” and 7 of the ratings being “cannot tell” vs 
“exclude.”
From the 29 studies included, 5 were randomly selected 
for interrater reliability ratings of the RCT-PQRS and 
the Cochrane Risk of Bias Tool. For the RCT-PQRS, 
Cohen’s Kappa was (κ)  =  0.62 and, for the Cochrane 
Risk of Bias, Cohen’s Kappa was (κ) = 0.73. According 
to Landis and Koch’s criteria, this represents a substan-
tial level of agreement.50
Meta-analyses and Meta-regressions
Positive Symptoms. The analysis for positive symptoms 
included 2698 participants. The pooled effect size for 
the 28 studies examining positive symptoms was −0.24 
(95% CI −0.32, −0.16, P < .001) (negative sign favors 
CBTp). These results indicated nonsignificant hetero-
geneity (Q = 26.87, P = .47) with an I2 =0%. When the 
two ARMS studies were excluded, the pooled effect size 
for the 26 studies was −0.26 (95% CI −0.34, −0.18, P 
< .001). These results indicated nonsignificant hetero-
geneity (Q  =  24.78, P  =  .47), with an I2 =0%. Finally, 
when in addition to the ARMS studies, the one VR and 
two self-help studies were removed, the pooled effect size 
for the 23 studies was −0.26 (95% CI −0.34, −0.17, P < 
.001). These findings also indicate nonsignificant heter-
ogeneity (Q = 20.57, P = .55) with an I2 =0%. Since ex-
cluding the ARMS, VR, and self-help studies made little 
difference to the overall pooled effect size, all 28 studies 
were included in the final meta-analysis; the forest plot is 
shown in figure 2. A weighted meta-regression indicated 
no effect of year on the effectiveness of CBTp on positive 
symptoms, F(1,26) = 0.00, P = .996, with an R2 = 0.001.
Delusions. When 15 out of the 28 studies that report a 
specific measure of delusions were analyzed, the pooled 
effect for these studies was −0.33 (95% CI −0.53, −0.14, 
P < .001). These studies were heterogeneous (Q = 32.80, 
P  =  .003) with an I2 =57%. Within this meta-analysis, 
there were two studies that reported that they were 
targeting only hallucinations and not delusions. When 
these studies were removed, the pooled effect size for 
the 890 participants was −0.36 (−0.59, −0.13, P = .002), 
with substantial heterogeneity (Q = 31.99, P = .001) with 
an I2 =62%. The forest plot for these studies is shown in 
figure 2.
A weighted meta-regression indicated a significant ef-
fect of year on the effectiveness of CBTp, F(1,11) = 5.99, 
P = .032, with an R2 = 0.594. In this model, the year of 
publication, t(11)  =  −2.44, P  =  .032, was a significant 
predictor of the effectiveness of CBTp on delusions, 
indicating that the effectiveness of CBTp increased with 
increasing year of publication. This finding persisted A
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when co-occurring hallucinations were controlled for, 
F(2,8) = 5.441, P = .032, with an R2 = 0.759, where the 
year of publication, t(8) = 2.72, P = .026, still significantly 
predicted CBTp effectiveness. This finding also persisted 
when methodological quality (RCT-PQRS) was 
controlled for as a confounding variable, F(3,7) = 13.34, 
Figure 2. Forest plot of studies in the meta-analysis of positive symptoms, delusions, hallucinations, and negative symptoms, respectively.
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P = .003, with an R2 = 0.923, where the year of publica-
tion t(7) = −4.29, P =  .004 continued to predict the ef-
fectiveness of CBTp on delusions. This finding suggests 
that methodological quality did not confound the rela-
tionship between year of publication and effectiveness. 
The interaction term between the methodological quality 
and year (RCT-PQRS × YEAR) was not significant, 
F(1,11) = 3.67, P = .082, with an R2 = 0.500, suggesting 
that methodological quality did not moderate the rela-
tionship between the effectiveness of CBTp on delusions 
and year of publication.
Hallucinations. When studies that reported a score for 
hallucinations were taken into account, the pooled ef-
fect for the 849 participants in the 16 studies was −0.26 
(95% CI −0.42, −0.11), P < .001. These studies indi-
cated nonsignificant heterogeneity (Q = 18.10, P =  .26) 
with an I2 =17%. The forest plot for these studies is 
shown in figure  2. A  weighted meta-regression indi-
cated a nonsignificant effect of year on the effectiveness 
of CBTp on hallucinations F(1,14)  =  0.43, P  =  .522, 
with an R2  =  0.173. This finding was unchanged when 
co-occurring delusions were controlled for F(2,8) = 1.67, 
P = .248, with an R2 = 0.543.
Negative Symptoms. When all studies that report nega-
tive symptoms were taken into account, the pooled effect 
for the 1761 participants in the 19 studies was −0.22 (95% 
CI −0.33, −0.12), P < .001. These studies were not heter-
ogeneous (Q = 20.32, P = .32) with an I2=11%. The forest 
plot for these studies is shown in figure  2. A  weighted 
meta-regression indicated a nonsignificant effect of 
year on the impact of CBTp on negative symptoms, 
F(1,16) = 0.747, P = .400, with an R2 = 0.211.
Publication Bias
Positive Symptoms. For positive symptoms, Begg and 
Mazumdar’s test generated nonsignificant Kendall’s 
τ of  −0.18 (z  =  1.32; P  =  .09, one tailed). Egger’s test 
generated an intercept of −0.80 (95% CI −1.79, 0.19; 
t[26]  =  1.65; P  =  .06, one tailed), which reflects trend-
level significance, suggesting that publication bias might 
well exist. Duval and Tweedie’s trim and fill procedure 
identified five potential missing studies and recomputed 
the new point estimate at −0.20 (95% CI −0.29, −0.11), 
which slightly affected the overall magnitude of the effect 
size.
Delusions and Hallucinations. Tests of publication bias 
for delusions and hallucinations were nonsignificant, 
suggesting that bias is not a major problem.
Negative Symptoms. For negative symptoms, Begg and 
Mazumdar’s test generated a significant Kendall’s τ of  
−0.29 (z = 1.75; P = .04, one tailed). Egger’s test generated 
an intercept of −0.91 (95% CI −2.22, 0.41; t[17] = 1.45; 
P  =  .08, one tailed), which reflects nonsignificance, 
suggesting that publication bias is not present. Duval and 
Tweedie’s trim and fill procedure, however, identified five 
potential missing studies and recomputed the new point 
estimate at −0.14 (95% CI −0.27, −0.02), which affected 
the overall magnitude of the effect size. All results of tests 
for publication bias are presented in table 2, with funnel 
plots in figure 3.
Methodological Quality
Ratings on the six domains of the Cochrane Risk of Bias 
were mainly low or unclear risk, and only a few studies 
were rated as high risk on certain domains.
Discussion
The aim of this systematic review and meta-analysis 
was to examine the effectiveness of CBTp for posi-
tive symptoms, delusions, hallucinations, and negative 
symptoms and to determine whether the effectiveness of 
CBTp changed across time. The results showed small-
to-medium significant effects favoring CBTp for posi-
tive symptoms, hallucinations, delusions, and negative 
symptoms. We had hypothesized an increase in the ef-
fectiveness of CBTp over time for positive symptoms, 
delusions, and hallucinations, but this effect was only 
observed for delusions. We found that methodological 
quality did not affect this finding, suggesting that this 
Table 2. Results of tests for publication bias for positive symptoms, delusions, hallucinations, and negative symptoms
Effect size (95% CI) Egger’s testb
Begg and 
Mazumdar’s 
testb
Symptoms Studies, n Unadjusted Trim and fill t P z P
Positive 28 −0.24 (−0.32; −0.16) −0.20 (−0.29; −0.11)a 1.65 .06 1.32 .09
Delusions 13 −0.36 (−0.59; −0.13) None 0.83 .21 0.79 .21
Hallucinations 16 −0.26 (−0.42; −0.11) None 0.47 .32 0.67 .25
Negative 19 −0.22 (−0.33; −0.12) −0.14 (−0.27; −0.02)a 1.45 .08 1.75 .04
Note: aFive studies were imputed. 
bTests were one-tailed.
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improvement in treatment effectiveness is probably not a 
result of changes in trial quality.
In terms of positive symptoms, the pooled effect size 
indicated a small significant effect of 0.24, favoring CBTp 
over TAU. When publication bias was assessed, the effect 
reduced to 0.20. Our finding is similar to that of Jauhar 
et al3 who found an effect size of 0.24. Wykes et al5 found 
a small-to-medium effect size of 0.37 but, as discussed in 
Jauhar et al, the authors used Glass’s approach in calcu-
lating effect size, which has been purported to inflate the 
effect size. When positive symptoms were examined indi-
vidually, the pooled effect size for delusions indicated a 
small-to-medium significant effect of 0.36 favoring CBTp 
and a pooled effect size of 0.26 for hallucinations. This 
suggests potential differences in the effect of CBTp on re-
duction of delusions and hallucinations and points to the 
importance of examining positive symptoms individually 
in future research.
In their recent meta-analysis assessing the effective-
ness of CBTp on delusions, van der Gaag et al9 reported 
the same effect size of 0.36 favoring CBTp. In terms of 
hallucinations, Jauhar et al3 found an effect size of 0.34, 
while van der Gaag et  al found an effect size of 0.44 
favoring CBTp. The effect sizes in these meta-analyses 
are higher than our finding but an important differ-
ence is that these published meta-analyses included any 
comparison condition (ie, supportive counseling, TAU, 
and psychoeducation) and pooled data when there was 
more than one control group. The meaning of this dif-
ference is unclear; however, it would suggest that when 
CBTp is compared with an active comparison group, it 
appears more effective for hallucination symptoms in 
some of the studies. Unfortunately, the authors of these 
meta-analyses did not report the means and SDs; this 
restricts the making of comparisons between the studies 
and highlights the importance of future meta-analyses to 
provide these statistics as they may provide additional in-
formation that may be helpful in determining why such 
differences may exist.
In our systematic review, as in other reviews,3,5 the hal-
lucination and delusion scores were averaged to generate 
a positive symptom score in studies that did not report 
an overall score. Since hallucinations and delusions cor-
relate well with one another8 (r = .44), there is good justi-
fication for such a composite score. However, it has been 
reported that many people experience only delusions 
or only hallucinations; averaging these subscales in 
individuals who experience only one of these symptoms 
may lead to a deflated score as a result of the loss of im-
portant information in terms of severity when the scores 
are averaged.8 In this meta-analysis, examining psychotic 
symptoms individually was shown to be more informa-
tive and meaningful than exploring positive symptoms as 
a syndrome as suggested in previous research.51–53
Figure 3. Funnel plot for studies in the meta-analysis examining positive symptoms, delusions, hallucinations, and negative symptoms. 
Open circles reflect the studies included in the meta-analysis; darkened circles reflect imputed studies; open diamond reflects the 
unadjusted magnitude of the effect size; darkened diamond reflects the adjusted magnitude of the effect size.
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Why has the Effectiveness of CBTp Increased for 
Delusions but not for Hallucinations?
The main finding in this meta-analysis is that the effec-
tiveness of CBTp increased for delusions but not for 
hallucinations or negative symptoms. It may be that 
the evolution in CBTp13 and developments in the un-
derstanding of the psychological mechanisms that con-
tribute to the formation, maintenance, and experience of 
psychotic symptoms have led to the improved effective-
ness of CBTp for delusions.
Some researchers propose that the focus of working 
with hallucinations is to change the relationship an indi-
vidual has with their voices (by challenging the power and 
omnipotence of the voices), leading to a reduction in dis-
tress rather than to a reduction in frequency.54 Although 
they acknowledge that a reduction in distress might lead 
to a reduction in the frequency of hallucinations, they as-
sert that this is not the focus of therapy. Since the current 
meta-analysis examined symptom reduction rather than 
distress reduction, we were unable to examine the effec-
tiveness of CBTp on distress and whether there was im-
provement across time.
One of the main limitations of assessing the effective-
ness of CBTp for delusions and hallucinations is that we 
did not always know what symptoms were targeted by 
the CBTp intervention. For example, only four studies in 
the hallucinations meta-analysis claimed to be targeting 
hallucinations only, while one study in the delusions 
meta-analysis claimed that it was specifically targeting 
paranoia. The rest of the studies either are not explicit 
in the symptom focus or they broadly state that they are 
targeting positive symptoms. Although the two meta-
analyses carried out here explored the effectiveness of 
CBTp on specific symptoms, we do not know what pro-
portion of these symptoms were targeted in each study. 
As a result, the interpretation of findings is difficult 
and, although delusions and hallucinations frequently 
co-occur, there are many people who experience one or 
the other. One study, eg, reported that delusions and 
hallucinations co-occurred on the Psychotic Symptom 
Rating Scale (PSYRATS) in 45% of the sample.8 The 
authors found that the mean score for individuals re-
porting hallucinations only was 27.6 (SD  =  6.7) but 
when combined with the whole group, including those 
who did not report hallucinations, the mean was smaller 
14.4 (SD  =  14.6). This difference indicates the loss 
of important information in terms of severity when 
the whole group, including those who do not experi-
ence hallucinations, is averaged. For people reporting 
delusions only, the discrepancy in means is smaller: 16.3 
(SD = 4.0), with a whole-sample mean of 13.5 (SD = 7.1). 
Averaging means for the whole sample, in cases where 
some participants do not experience hallucinations and 
where hallucinations were not the targeted intervention 
(even in those experiencing hallucinations), may be an-
other reason why no increase in the effectiveness of CBTp 
for hallucinations was observed across time. Since we do 
not know what proportion of the intervention within 
the studies actually targeted hallucinations, the observed 
effect of CBTp for hallucinations may not be a true re-
flection of the actual effect of interventions targeting 
hallucinations specifically.
One of the main limitations of assessing negative 
symptoms in the current systematic review was that there 
was usually no information in the paper as to what propor-
tion of therapy goals were targeting negative symptoms. 
In the current meta-analysis, there was only one study 
that focused on targeting negative symptoms.55 Since it 
is not certain whether the interventions in the studies in-
cluded in the present meta-analysis actually targeted neg-
ative symptoms, the effect size observed (0.22) may not 
be a true reflection of the actual effect of targeted treat-
ment. A distinction between primary or secondary nega-
tive symptoms would also have been helpful because, if  
a decrease in negative symptoms were observed, it could 
have been a result of a reduction in positive symptoms 
rather than through the direct targeted treatment of neg-
ative symptoms. This distinction is important as treat-
ment for negative symptoms poses a major challenge for 
mental health services, and more effective treatments are 
needed.56 Velthorst et  al11 reported similar findings to 
ours, an effect of 0.09 in favor of CBTp when negative 
symptoms were examined as secondary outcomes and an 
effect of 0.16 when negative symptoms were examined as 
primary outcomes.
Further Research
A closer examination of the studies in the current meta-
analysis showed substantial variability in terms of manual 
use: some studies reported a manualized approach 
with adherence and fidelity ratings, others reported not 
using a manualized approach, while yet others reported 
amalgamating several different manuals. Morrison 
proposed that, in order to replicate outcomes, RCTs 
should show adherence and fidelity to the trial’s models 
and manualized protocol.57 This process might ascertain 
whether the RCTs are providing the treatment they set 
out to deliver. It could also help identify which models 
or manuals are associated with more effective outcomes. 
Furthermore, an assessment of long-term effectiveness 
using follow-up data could indicate whether effects per-
sist, increase, or decrease with time.
Limitations
In addition to the limitations above, others need 
to be considered. First, the current meta-analyses 
only examined researcher-rated symptom outcomes. 
Previous research has shown poor correlations between 
service users’ subjective ratings and clinicians’ ratings 
of  psychotic symptoms.58 It would, therefore, have been 
valuable to examine both ratings; however, since most 
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of  the studies reported researcher-rated outcomes, this 
would have been a much smaller analysis. Second, the 
meta-analyses focused on clinical outcomes rather than 
any other outcome that might have been important to 
the service users, such as quality of  life or subjective 
recovery. Since recovery in psychosis is a personally 
defined journey59 that is not always associated with 
symptom reduction, it would have been valuable to 
examine subjective recovery outcomes. Fortunately, 
there is a growing trend to include service user out-
come measures and it may be possible for future 
reviewers to assimilate data from primary studies that 
report these items. Third, most studies included in the 
meta-analysis did not provide adherence ratings and 
the quality of  the intervention, and adherence to the 
model is unknown. Fourth, length of  treatment was 
not assessed, and the effect of  treatment dosage is un-
known. Fifth, the current meta-analyses examined data 
at the end of  treatment. This limits our understanding 
whether the effects persist, increase, or decrease with 
time. Sixth, the effects of  antipsychotic medication 
were not controlled for. Perhaps it was an evolution 
in antipsychotic medication that led to an increase in 
the effectiveness of  the observed CBTp rather than the 
effects of  the evolution of  CBTp. Although this could 
be the case, the TAU group usually included medica-
tion as one of  the treatments, so this does not seem to 
be a plausible argument. It is plausible that the effect 
of  antipsychotic medication was to help clients engage 
better in therapy, but this notion would need further 
examination.
Conclusion
The most recent National Clinical Audit of Psychosis60 re-
ported that only 26% of service users were offered CBTp. 
The finding in the current meta-analysis suggests that 
CBTp can be effective at reducing psychotic symptoms 
and that the effectiveness of CBTp for delusions has 
increased over time. This finding is important because 
it challenges arguments that CBTp has been oversold. 
Instead, the clinical implications of this systematic review 
are that CBTp should continue to be offered as a psy-
chological intervention to service users with psychosis, 
especially those experiencing delusions. On a final note, 
it is important to note that basing treatment decisions 
on meta-analytic findings can be difficult as the data 
rely on “average” outcomes and there are no “average” 
service users. Evidencing the efficacy of treatment on the 
outcomes that are important to service users (eg, distress) 
seems an important next step.
Supplementary Material
Supplementary data are available at Schizophrenia 
Bulletin Open online.
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